09:26 AM EDT, 03/20/2025 (MT Newswires) -- Aptevo Therapeutics ( APVO ) said Thursday that two additional acute myeloid leukemia patients achieved remission within 30 days of treatment in a trial evaluating mipletamig with standard therapy for patients unfit for intensive chemotherapy.

The company said nine of ten frontline patients across two studies have now reached remission with the triplet combination of mipletamig, venetoclax, and azacitidine.

Cohort 2 of the trial is nearly fully enrolled, with patients receiving the same dose used in an earlier expansion study, Aptevo said, adding that one patient in the latest cohort progressed and died from causes unrelated to the treatment.